ADI-270

N/A

Report date: 2025/02/18 11:53:01

Base Information

Drug NameADI-270

Drug Alias NameAllogeneic gamma delta T cell therapyADI-270

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Gamma delta T-cell therapy

Mechanisms of ActionCD70 antigen modulators

TargetsCD70 antigen

Therapy Area/IndicationsCarcinoma, Renal Cell

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesAdicet Bio Inc

China Registration ClassN/A

Develop Information

Active CompaniesAdicet Bio Inc

Inactive CompaniesN/A

Active IndicationsCarcinoma, Renal Cell

Inactive IndicationsN/A

Other Information

ATC CodeN/A